Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating. Dova Pharmaceuticals’ rating score has improved by 40.1% from 90 days ago as a result of a number of analysts’ upgrades and downgrades.
Analysts have set a twelve-month consensus price target of $32.33 for the company, according to Zacks. Zacks has also given Dova Pharmaceuticals an industry rank of 115 out of 265 based on the ratings given to its competitors.
DOVA has been the subject of several recent research reports. Leerink Swann upgraded Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 price target for the company in a research report on Tuesday, September 26th. Zacks Investment Research raised Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 price target on the stock in a research note on Wednesday, October 11th. Jefferies Group LLC assumed coverage on Dova Pharmaceuticals in a research report on Monday, July 24th. They set a “buy” rating and a $30.00 price objective on the stock. Finally, J P Morgan Chase & Co assumed coverage on Dova Pharmaceuticals in a report on Monday, July 24th. They issued an “overweight” rating and a $35.00 price objective on the stock.
In other Dova Pharmaceuticals news, Director Steven M. Goldman bought 20,169 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were acquired at an average cost of $22.23 per share, with a total value of $448,356.87. Following the completion of the transaction, the director now owns 81,158 shares in the company, valued at $1,804,142.34. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Paul B. Manning bought 25,870 shares of the company’s stock in a transaction dated Wednesday, August 16th. The shares were acquired at an average cost of $22.30 per share, for a total transaction of $576,901.00. The disclosure for this purchase can be found here.
A number of large investors have recently bought and sold shares of the stock. FMR LLC acquired a new position in Dova Pharmaceuticals in the second quarter worth about $43,969,000. Fosun International Ltd acquired a new position in Dova Pharmaceuticals in the second quarter worth about $14,489,000. Paulson & CO. Inc. acquired a new position in Dova Pharmaceuticals in the second quarter worth about $13,856,000. Wells Fargo & Company MN acquired a new position in Dova Pharmaceuticals in the second quarter worth about $4,458,000. Finally, Nexthera Capital LP acquired a new position in Dova Pharmaceuticals in the second quarter valued at approximately $4,415,000. Institutional investors and hedge funds own 23.53% of the company’s stock.
Shares of Dova Pharmaceuticals (DOVA) traded down $0.14 during trading on Thursday, reaching $24.95. The company’s stock had a trading volume of 34,377 shares, compared to its average volume of 72,362. Dova Pharmaceuticals has a 12 month low of $16.98 and a 12 month high of $29.99.
Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings data on Thursday, August 10th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.08). equities research analysts expect that Dova Pharmaceuticals will post -1.4 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Set $32.33 Price Target for Dova Pharmaceuticals, Inc. (DOVA)” was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/11/05/zacks-analysts-set-32-33-price-target-for-dova-pharmaceuticals-inc-dova.html.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Dova Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dova Pharmaceuticals Inc. and related companies.